| 1,10-Phenanthroline | The serum concentration of Midazolam can be increased when it is combined with 1,10-Phenanthroline. | Experimental |
| 3,4-Dichloroisocoumarin | The serum concentration of Midazolam can be increased when it is combined with 3,4-Dichloroisocoumarin. | Experimental |
| 4-(2-Aminoethyl)Benzenesulfonyl Fluoride | The serum concentration of Midazolam can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE. | Experimental |
| 7-Nitroindazole | The risk or severity of adverse effects can be increased when Midazolam is combined with 7-Nitroindazole. | Experimental |
| Acebutolol | The serum concentration of Acebutolol can be decreased when it is combined with Midazolam. | Approved |
| Acepromazine | The risk or severity of adverse effects can be increased when Midazolam is combined with Acepromazine. | Approved, Vet Approved |
| Aceprometazine | The risk or severity of adverse effects can be increased when Midazolam is combined with Aceprometazine. | Approved |
| Acetaminophen | The serum concentration of Acetaminophen can be decreased when it is combined with Midazolam. | Approved |
| Acetylsalicylic acid | The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Midazolam. | Approved, Vet Approved |
| Adipiplon | The risk or severity of adverse effects can be increased when Midazolam is combined with adipiplon. | Investigational |
| Afatinib | The serum concentration of Afatinib can be decreased when it is combined with Midazolam. | Approved |
| Agomelatine | The risk or severity of adverse effects can be increased when Midazolam is combined with Agomelatine. | Approved, Investigational |
| Albendazole | The serum concentration of Midazolam can be increased when it is combined with Albendazole. | Approved, Vet Approved |
| Aldosterone | The serum concentration of Midazolam can be decreased when it is combined with Aldosterone. | Experimental |
| Alectinib | The serum concentration of Midazolam can be increased when it is combined with Alectinib. | Approved |
| Alfaxalone | The risk or severity of adverse effects can be increased when Midazolam is combined with Alfaxalone. | Vet Approved |
| Alfentanil | The serum concentration of Midazolam can be increased when it is combined with Alfentanil. | Approved, Illicit |
| Alitretinoin | The serum concentration of Alitretinoin can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Allopregnanolone | The risk or severity of adverse effects can be increased when Midazolam is combined with Sage 547. | Investigational |
| Alogliptin | The serum concentration of Midazolam can be increased when it is combined with Alogliptin. | Approved |
| Alpha-1-proteinase inhibitor | The serum concentration of Midazolam can be increased when it is combined with Alpha-1-proteinase inhibitor. | Approved |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Midazolam is combined with Alphacetylmethadol. | Experimental, Illicit |
| Alprazolam | The risk or severity of adverse effects can be increased when Alprazolam is combined with Midazolam. | Approved, Illicit, Investigational |
| Amantadine | The serum concentration of Midazolam can be increased when it is combined with Amantadine. | Approved |
| Ambrisentan | The serum concentration of Ambrisentan can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Ambroxol acefyllinate | The therapeutic efficacy of Midazolam can be decreased when used in combination with Ambroxol acefyllinate. | Experimental |
| Aminohippuric acid | The serum concentration of Midazolam can be increased when it is combined with Aminohippuric acid. | Approved |
| Aminophylline | The therapeutic efficacy of Midazolam can be decreased when used in combination with Aminophylline. | Approved |
| Amiodarone | The metabolism of Midazolam can be decreased when combined with Amiodarone. | Approved, Investigational |
| Amisulpride | The risk or severity of adverse effects can be increased when Midazolam is combined with Amisulpride. | Approved, Investigational |
| Amitriptyline | The serum concentration of Amitriptyline can be decreased when it is combined with Midazolam. | Approved |
| Amlodipine | The serum concentration of Midazolam can be increased when it is combined with Amlodipine. | Approved |
| Amobarbital | The risk or severity of adverse effects can be increased when Midazolam is combined with Amobarbital. | Approved, Illicit |
| Amoxapine | The risk or severity of adverse effects can be increased when Midazolam is combined with Amoxapine. | Approved |
| Amperozide | The risk or severity of adverse effects can be increased when Midazolam is combined with Amperozide. | Experimental |
| Amprenavir | The serum concentration of Midazolam can be increased when it is combined with Amprenavir. | Approved |
| Amsacrine | The serum concentration of Midazolam can be increased when it is combined with Amsacrine. | Approved |
| Antithrombin III human | The serum concentration of Midazolam can be increased when it is combined with Antithrombin III human. | Approved |
| Apixaban | The serum concentration of Midazolam can be increased when it is combined with Apixaban. | Approved |
| Aprepitant | The serum concentration of Midazolam can be increased when it is combined with Aprepitant. | Approved, Investigational |
| Aprotinin | The serum concentration of Midazolam can be increased when it is combined with Aprotinin. | Approved, Withdrawn |
| Argatroban | The serum concentration of Midazolam can be increased when it is combined with Argatroban. | Approved, Investigational |
| Aripiprazole | The risk or severity of adverse effects can be increased when Midazolam is combined with Aripiprazole. | Approved, Investigational |
| Arsenic trioxide | The serum concentration of Arsenic trioxide can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Articaine | The risk or severity of adverse effects can be increased when Midazolam is combined with Articaine. | Approved |
| Asenapine | The risk or severity of adverse effects can be increased when Midazolam is combined with Asenapine. | Approved |
| Astemizole | The serum concentration of Midazolam can be increased when it is combined with Astemizole. | Approved, Withdrawn |
| Asunaprevir | The serum concentration of Midazolam can be increased when it is combined with Asunaprevir. | Approved, Investigational |
| Atazanavir | The serum concentration of Midazolam can be increased when it is combined with Atazanavir. | Approved, Investigational |
| Atenolol | The serum concentration of Atenolol can be decreased when it is combined with Midazolam. | Approved |
| Atomoxetine | The metabolism of Midazolam can be decreased when combined with Atomoxetine. | Approved |
| Atorvastatin | The serum concentration of Midazolam can be increased when it is combined with Atorvastatin. | Approved |
| Axitinib | The serum concentration of Axitinib can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Azaperone | The risk or severity of adverse effects can be increased when Midazolam is combined with Azaperone. | Vet Approved |
| Azelastine | Midazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine. | Approved |
| Azelastine | The serum concentration of Midazolam can be increased when it is combined with Azelastine. | Approved |
| Azithromycin | The serum concentration of Midazolam can be increased when it is combined with Azithromycin. | Approved |
| Baclofen | The risk or severity of adverse effects can be increased when Midazolam is combined with Baclofen. | Approved |
| Barbital | The risk or severity of adverse effects can be increased when Midazolam is combined with Barbital. | Illicit |
| Batimastat | The serum concentration of Midazolam can be increased when it is combined with Batimastat. | Experimental |
| Benazepril | The serum concentration of Midazolam can be increased when it is combined with Benazepril. | Approved, Investigational |
| Benperidol | The risk or severity of adverse effects can be increased when Midazolam is combined with Benperidol. | Investigational |
| Benzamidine | The serum concentration of Midazolam can be increased when it is combined with Benzamidine. | Experimental |
| Benzocaine | The serum concentration of Midazolam can be increased when it is combined with Benzocaine. | Approved |
| Benzyl alcohol | The risk or severity of adverse effects can be increased when Midazolam is combined with Benzyl alcohol. | Approved |
| Bepridil | The serum concentration of Midazolam can be increased when it is combined with Bepridil. | Approved, Withdrawn |
| Betamethasone | The serum concentration of Betamethasone can be decreased when it is combined with Midazolam. | Approved, Vet Approved |
| Bexarotene | The serum concentration of Midazolam can be decreased when it is combined with Bexarotene. | Approved, Investigational |
| Biperiden | The serum concentration of Midazolam can be increased when it is combined with Biperiden. | Approved |
| Bivalirudin | The serum concentration of Midazolam can be increased when it is combined with Bivalirudin. | Approved, Investigational |
| Boceprevir | The serum concentration of Midazolam can be increased when it is combined with Boceprevir. | Withdrawn |
| Bortezomib | The metabolism of Midazolam can be decreased when combined with Bortezomib. | Approved, Investigational |
| Bosentan | The serum concentration of Midazolam can be decreased when it is combined with Bosentan. | Approved, Investigational |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Midazolam. | Approved |
| Brentuximab vedotin | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Midazolam. | Approved |
| Brexpiprazole | The risk or severity of adverse effects can be increased when Midazolam is combined with Brexpiprazole. | Approved |
| Brimonidine | The risk or severity of adverse effects can be increased when Midazolam is combined with Brimonidine. | Approved |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Midazolam. | Approved |
| Bromazepam | The risk or severity of adverse effects can be increased when Midazolam is combined with Bromazepam. | Approved, Illicit |
| Bromocriptine | The serum concentration of Bromocriptine can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Brompheniramine | The risk or severity of adverse effects can be increased when Midazolam is combined with Brompheniramine. | Approved |
| Brotizolam | The risk or severity of adverse effects can be increased when Midazolam is combined with Brotizolam. | Approved, Withdrawn |
| Bupivacaine | The risk or severity of adverse effects can be increased when Bupivacaine is combined with Midazolam. | Approved, Investigational |
| Buprenorphine | Midazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. | Approved, Illicit, Investigational, Vet Approved |
| Buspirone | The serum concentration of Midazolam can be increased when it is combined with Buspirone. | Approved, Investigational |
| Butabarbital | The risk or severity of adverse effects can be increased when Butabarbital is combined with Midazolam. | Approved, Illicit |
| Butacaine | The risk or severity of adverse effects can be increased when Midazolam is combined with Butacaine. | Vet Approved |
| Butalbital | The risk or severity of adverse effects can be increased when Midazolam is combined with Butalbital. | Approved, Illicit |
| Butamben | The risk or severity of adverse effects can be increased when Midazolam is combined with Butamben. | Approved |
| Butethal | The risk or severity of adverse effects can be increased when Midazolam is combined with Butethal. | Approved, Illicit |
| Butorphanol | The risk or severity of adverse effects can be increased when Butorphanol is combined with Midazolam. | Approved, Illicit, Vet Approved |
| Cabazitaxel | The serum concentration of Cabazitaxel can be decreased when it is combined with Midazolam. | Approved |
| Caffeine | The serum concentration of Caffeine can be decreased when it is combined with Midazolam. | Approved |
| Camptothecin | The serum concentration of Camptothecin can be decreased when it is combined with Midazolam. | Experimental |
| Canagliflozin | The serum concentration of Canagliflozin can be decreased when it is combined with Midazolam. | Approved |
| Candesartan | The serum concentration of Midazolam can be increased when it is combined with Candesartan. | Approved |
| Candoxatril | The serum concentration of Midazolam can be increased when it is combined with Candoxatril. | Experimental |
| Candoxatrilat | The serum concentration of Midazolam can be increased when it is combined with Candoxatrilat. | Experimental |
| Captopril | The serum concentration of Midazolam can be increased when it is combined with Captopril. | Approved |
| Carbamazepine | The metabolism of Midazolam can be increased when combined with Carbamazepine. | Approved, Investigational |
| Carbinoxamine | The risk or severity of adverse effects can be increased when Midazolam is combined with Carbinoxamine. | Approved |
| Carbomycin | The serum concentration of Midazolam can be increased when it is combined with Carbomycin. | Vet Approved |
| Carfentanil | The risk or severity of adverse effects can be increased when Midazolam is combined with Carfentanil. | Illicit, Vet Approved |
| Carfilzomib | The serum concentration of Carfilzomib can be decreased when it is combined with Midazolam. | Approved |
| Carisoprodol | The risk or severity of adverse effects can be increased when Midazolam is combined with Carisoprodol. | Approved |
| Carvedilol | The serum concentration of Midazolam can be increased when it is combined with Carvedilol. | Approved, Investigational |
| Caspofungin | The serum concentration of Midazolam can be increased when it is combined with Caspofungin. | Approved |
| Ceritinib | The serum concentration of Midazolam can be increased when it is combined with Ceritinib. | Approved |
| Cerivastatin | The serum concentration of Cerivastatin can be decreased when it is combined with Midazolam. | Withdrawn |
| Cetirizine | The risk or severity of adverse effects can be increased when Midazolam is combined with Cetirizine. | Approved |
| Chloral hydrate | The risk or severity of adverse effects can be increased when Midazolam is combined with Chloral hydrate. | Approved, Illicit, Vet Approved |
| Chlordiazepoxide | The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Midazolam. | Approved, Illicit |
| Chlormezanone | The risk or severity of adverse effects can be increased when Midazolam is combined with Chlormezanone. | Approved, Withdrawn |
| Chloroprocaine | The risk or severity of adverse effects can be increased when Midazolam is combined with Chloroprocaine. | Approved |
| Chloroquine | The serum concentration of Midazolam can be increased when it is combined with Chloroquine. | Approved, Vet Approved |
| Chlorphenamine | The risk or severity of adverse effects can be increased when Midazolam is combined with Chlorphenamine. | Approved |
| Chlorpromazine | The serum concentration of Chlorpromazine can be decreased when it is combined with Midazolam. | Approved, Vet Approved |
| Chlorpropamide | The serum concentration of Midazolam can be increased when it is combined with Chlorpropamide. | Approved |
| Chlorprothixene | The serum concentration of Midazolam can be increased when it is combined with Chlorprothixene. | Approved, Withdrawn |
| Chlorzoxazone | The risk or severity of adverse effects can be increased when Midazolam is combined with Chlorzoxazone. | Approved |
| Cholesterol | The serum concentration of Midazolam can be increased when it is combined with Cholesterol. | Experimental |
| Cholic Acid | The serum concentration of Midazolam can be decreased when it is combined with Cholic Acid. | Approved |
| Chymostatin | The serum concentration of Midazolam can be increased when it is combined with Chymostatin. | Experimental |
| Cilastatin | The serum concentration of Midazolam can be increased when it is combined with Cilastatin. | Approved |
| Cilazapril | The serum concentration of Midazolam can be increased when it is combined with Cilazapril. | Approved |
| Cimetidine | The serum concentration of Midazolam can be decreased when it is combined with Cimetidine. | Approved |
| Cinchocaine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Midazolam. | Approved, Vet Approved |
| Ciprofloxacin | The serum concentration of Ciprofloxacin can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Cisplatin | The serum concentration of Cisplatin can be decreased when it is combined with Midazolam. | Approved |
| Citalopram | The serum concentration of Citalopram can be decreased when it is combined with Midazolam. | Approved |
| Clarithromycin | The serum concentration of Midazolam can be increased when it is combined with Clarithromycin. | Approved |
| Clemastine | The metabolism of Midazolam can be decreased when combined with Clemastine. | Approved |
| Clidinium | The risk or severity of adverse effects can be increased when Midazolam is combined with Clidinium. | Approved |
| Clobazam | The serum concentration of Clobazam can be decreased when it is combined with Midazolam. | Approved, Illicit |
| Clofazimine | The serum concentration of Midazolam can be increased when it is combined with Clofazimine. | Approved, Investigational |
| clomethiazole | The risk or severity of adverse effects can be increased when Midazolam is combined with clomethiazole. | Investigational |
| Clomifene | The serum concentration of Clomifene can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Clomipramine | The serum concentration of Midazolam can be increased when it is combined with Clomipramine. | Approved, Vet Approved |
| Clonazepam | The risk or severity of adverse effects can be increased when Midazolam is combined with Clonazepam. | Approved, Illicit |
| Clonidine | The serum concentration of Clonidine can be decreased when it is combined with Midazolam. | Approved |
| Clopidogrel | The serum concentration of Clopidogrel can be decreased when it is combined with Midazolam. | Approved, Nutraceutical |
| Clorazepate | The risk or severity of adverse effects can be increased when Clorazepate is combined with Midazolam. | Approved, Illicit |
| Clotrimazole | The metabolism of Midazolam can be decreased when combined with Clotrimazole. | Approved, Vet Approved |
| Clozapine | The risk or severity of adverse effects can be increased when Midazolam is combined with Clozapine. | Approved |
| Cobicistat | The serum concentration of Midazolam can be increased when it is combined with Cobicistat. | Approved |
| Cobimetinib | The serum concentration of Cobimetinib can be decreased when it is combined with Midazolam. | Approved |
| Cocaine | The risk or severity of adverse effects can be increased when Midazolam is combined with Cocaine. | Approved, Illicit |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with Midazolam. | Approved, Illicit |
| Colchicine | The serum concentration of Colchicine can be increased when it is combined with Midazolam. | Approved |
| Colforsin | The serum concentration of Midazolam can be increased when it is combined with Colforsin. | Experimental |
| Conivaptan | The serum concentration of Midazolam can be increased when it is combined with Conivaptan. | Approved, Investigational |
| Conjugated estrogens | The serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Midazolam. | Approved |
| Crizotinib | The metabolism of Midazolam can be decreased when combined with Crizotinib. | Approved |
| Cyclizine | The risk or severity of adverse effects can be increased when Midazolam is combined with Cyclizine. | Approved |
| Cyclobenzaprine | The risk or severity of adverse effects can be increased when Midazolam is combined with Cyclobenzaprine. | Approved |
| Cyclophosphamide | The serum concentration of Midazolam can be increased when it is combined with Cyclophosphamide. | Approved, Investigational |
| Cyclosporine | The metabolism of Midazolam can be decreased when combined with Cyclosporine. | Approved, Investigational, Vet Approved |
| Cyproheptadine | The risk or severity of adverse effects can be increased when Midazolam is combined with Cyproheptadine. | Approved |
| Dabigatran etexilate | The serum concentration of Dabigatran etexilate can be decreased when it is combined with Midazolam. | Approved |
| Dabrafenib | The serum concentration of Midazolam can be decreased when it is combined with Dabrafenib. | Approved |
| Daclatasvir | The serum concentration of Midazolam can be increased when it is combined with Daclatasvir. | Approved |
| Dactinomycin | The serum concentration of Dactinomycin can be decreased when it is combined with Midazolam. | Approved |
| Dantrolene | The risk or severity of adverse effects can be increased when Midazolam is combined with Dantrolene. | Approved |
| Dapagliflozin | The serum concentration of Dapagliflozin can be decreased when it is combined with Midazolam. | Approved |
| Dapiprazole | The risk or severity of adverse effects can be increased when Dapiprazole is combined with Midazolam. | Approved |
| Dapoxetine | The risk or severity of adverse effects can be increased when Midazolam is combined with Dapoxetine. | Investigational |
| Darexaban | The serum concentration of Midazolam can be increased when it is combined with Ym150. | Investigational |
| Darunavir | The serum concentration of Midazolam can be increased when it is combined with Darunavir. | Approved |
| Dasatinib | The serum concentration of Midazolam can be increased when it is combined with Dasatinib. | Approved, Investigational |
| Daunorubicin | The serum concentration of Daunorubicin can be decreased when it is combined with Midazolam. | Approved |
| Debrisoquin | The serum concentration of Debrisoquin can be decreased when it is combined with Midazolam. | Approved |
| Deferasirox | The serum concentration of Midazolam can be decreased when it is combined with Deferasirox. | Approved, Investigational |
| Delavirdine | The metabolism of Midazolam can be decreased when combined with Delavirdine. | Approved |
| Deramciclane | The risk or severity of adverse effects can be increased when Midazolam is combined with deramciclane. | Investigational |
| Desflurane | The risk or severity of adverse effects can be increased when Midazolam is combined with Desflurane. | Approved |
| Desipramine | The serum concentration of Midazolam can be increased when it is combined with Desipramine. | Approved |
| Desloratadine | The serum concentration of Midazolam can be increased when it is combined with Desloratadine. | Approved, Investigational |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Midazolam is combined with Desvenlafaxine. | Approved |
| Detomidine | The risk or severity of adverse effects can be increased when Midazolam is combined with Detomidine. | Vet Approved |
| Dexamethasone | The serum concentration of Midazolam can be decreased when it is combined with Dexamethasone. | Approved, Investigational, Vet Approved |
| Dexbrompheniramine | The risk or severity of adverse effects can be increased when Midazolam is combined with Dexbrompheniramine. | Approved |
| Dexmedetomidine | The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Midazolam. | Approved, Vet Approved |
| Dextromethorphan | The serum concentration of Midazolam can be increased when it is combined with Dextromethorphan. | Approved |
| Dextromoramide | The risk or severity of adverse effects can be increased when Midazolam is combined with Dextromoramide. | Experimental, Illicit |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Midazolam. | Approved, Illicit, Withdrawn |
| Dezocine | The risk or severity of adverse effects can be increased when Midazolam is combined with Dezocine. | Approved |
| Diazepam | The serum concentration of Diazepam can be decreased when it is combined with Midazolam. | Approved, Illicit, Vet Approved |
| Diclofenac | The serum concentration of Midazolam can be increased when it is combined with Diclofenac. | Approved, Vet Approved |
| Diethylstilbestrol | The serum concentration of Diethylstilbestrol can be decreased when it is combined with Midazolam. | Approved |
| Difenoxin | The risk or severity of adverse effects can be increased when Midazolam is combined with Difenoxin. | Approved, Illicit |
| Digitoxin | The serum concentration of Digitoxin can be decreased when it is combined with Midazolam. | Approved |
| Digoxin | The serum concentration of Midazolam can be decreased when it is combined with Digoxin. | Approved |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Midazolam is combined with Dihydrocodeine. | Approved, Illicit |
| Dihydroergotamine | The metabolism of Midazolam can be decreased when combined with Dihydroergotamine. | Approved |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Midazolam is combined with Dihydroetorphine. | Experimental, Illicit |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Midazolam is combined with Dihydromorphine. | Experimental, Illicit |
| Dihydrotestosterone | The serum concentration of Dihydrotestosterone can be decreased when it is combined with Midazolam. | Illicit |
| Diltiazem | The metabolism of Midazolam can be decreased when combined with Diltiazem. | Approved |
| Dimenhydrinate | The risk or severity of adverse effects can be increased when Midazolam is combined with Dimenhydrinate. | Approved |
| Diphenhydramine | The risk or severity of adverse effects can be increased when Midazolam is combined with Diphenhydramine. | Approved |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Midazolam is combined with Diphenoxylate. | Approved, Illicit |
| Dipyridamole | The serum concentration of Dipyridamole can be decreased when it is combined with Midazolam. | Approved |
| Docetaxel | The serum concentration of Docetaxel can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Domperidone | The serum concentration of Domperidone can be decreased when it is combined with Midazolam. | Approved, Investigational, Vet Approved |
| Doramectin | The risk or severity of adverse effects can be increased when Midazolam is combined with Doramectin. | Vet Approved |
| Doxazosin | The serum concentration of Midazolam can be increased when it is combined with Doxazosin. | Approved |
| Doxepin | The serum concentration of Midazolam can be increased when it is combined with Doxepin. | Approved |
| Doxorubicin | The serum concentration of Doxorubicin can be increased when it is combined with Midazolam. | Approved, Investigational |
| Doxorubicin | The serum concentration of Doxorubicin can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Doxycycline | The metabolism of Midazolam can be decreased when combined with Doxycycline. | Approved, Investigational, Vet Approved |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Midazolam. | Approved, Vet Approved |
| DPDPE | The risk or severity of adverse effects can be increased when Midazolam is combined with DPDPE. | Investigational |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Midazolam. | Approved, Illicit |
| Dronedarone | The metabolism of Midazolam can be decreased when combined with Dronedarone. | Approved |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Midazolam. | Approved, Vet Approved |
| Drotebanol | The risk or severity of adverse effects can be increased when Midazolam is combined with Drotebanol. | Experimental, Illicit |
| Duloxetine | The risk or severity of adverse effects can be increased when Midazolam is combined with Duloxetine. | Approved |
| Dyclonine | The risk or severity of adverse effects can be increased when Dyclonine is combined with Midazolam. | Approved |
| Dyphylline | The therapeutic efficacy of Midazolam can be decreased when used in combination with Dyphylline. | Approved |
| Ecabet | The serum concentration of Midazolam can be increased when it is combined with Ecabet. | Approved, Investigational |
| Ecgonine | The risk or severity of adverse effects can be increased when Midazolam is combined with Ecgonine. | Experimental, Illicit |
| Ecopipam | The risk or severity of adverse effects can be increased when Midazolam is combined with Ecopipam. | Investigational |
| Edoxaban | The serum concentration of Midazolam can be increased when it is combined with Edoxaban. | Approved |
| Efavirenz | The serum concentration of Midazolam can be decreased when it is combined with Efavirenz. | Approved, Investigational |
| Elafin | The serum concentration of Midazolam can be increased when it is combined with Elafin. | Investigational |
| Elbasvir | The serum concentration of Midazolam can be increased when it is combined with Elbasvir. | Approved |
| Eletriptan | The serum concentration of Eletriptan can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Eltanolone | The risk or severity of adverse effects can be increased when Midazolam is combined with Pregnanolone. | Investigational |
| Enalapril | The serum concentration of Midazolam can be increased when it is combined with Enalapril. | Approved, Vet Approved |
| Enalaprilat | The serum concentration of Midazolam can be increased when it is combined with Enalaprilat. | Approved |
| Enalkiren | The serum concentration of Midazolam can be increased when it is combined with Enalkiren. | Experimental |
| Enflurane | The risk or severity of adverse effects can be increased when Enflurane is combined with Midazolam. | Approved, Vet Approved |
| Entacapone | The risk or severity of adverse effects can be increased when Midazolam is combined with Entacapone. | Approved, Investigational |
| Enzalutamide | The serum concentration of Midazolam can be decreased when it is combined with Enzalutamide. | Approved |
| Epinastine | The serum concentration of Epinastine can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Ergonovine | The serum concentration of Midazolam can be increased when it is combined with Ergonovine. | Approved |
| Ergotamine | The serum concentration of Midazolam can be increased when it is combined with Ergotamine. | Approved |
| Erlotinib | The serum concentration of Erlotinib can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Erythromycin | The serum concentration of Midazolam can be increased when it is combined with Erythromycin. | Approved, Vet Approved |
| Escitalopram | The risk or severity of adverse effects can be increased when Midazolam is combined with Escitalopram. | Approved, Investigational |
| Eslicarbazepine acetate | The serum concentration of Midazolam can be decreased when it is combined with Eslicarbazepine acetate. | Approved |
| Estazolam | The risk or severity of adverse effects can be increased when Midazolam is combined with Estazolam. | Approved, Illicit |
| Estradiol | The serum concentration of Estradiol can be decreased when it is combined with Midazolam. | Approved, Investigational, Vet Approved |
| Estramustine | The serum concentration of Midazolam can be increased when it is combined with Estramustine. | Approved |
| Estriol | The serum concentration of Estriol can be decreased when it is combined with Midazolam. | Approved, Vet Approved |
| Estrone | The serum concentration of Estrone can be decreased when it is combined with Midazolam. | Approved |
| Eszopiclone | The risk or severity of adverse effects can be increased when Eszopiclone is combined with Midazolam. | Approved |
| Ethanol | Midazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol. | Approved |
| Ethchlorvynol | The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Midazolam. | Approved, Illicit, Withdrawn |
| Ethinyl Estradiol | The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Midazolam. | Approved |
| Ethosuximide | The risk or severity of adverse effects can be increased when Midazolam is combined with Ethosuximide. | Approved |
| Ethotoin | The risk or severity of adverse effects can be increased when Midazolam is combined with Ethotoin. | Approved |
| Ethyl carbamate | The risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl carbamate. | Withdrawn |
| Ethyl loflazepate | The risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl loflazepate. | Approved, Illicit |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Midazolam is combined with Ethylmorphine. | Approved, Illicit |
| Etidocaine | The risk or severity of adverse effects can be increased when Midazolam is combined with Etidocaine. | Approved |
| Etifoxine | The risk or severity of adverse effects can be increased when Midazolam is combined with Etifoxine. | Withdrawn |
| Etizolam | The risk or severity of adverse effects can be increased when Midazolam is combined with Etizolam. | Approved |
| Etomidate | The risk or severity of adverse effects can be increased when Etomidate is combined with Midazolam. | Approved |
| Etoperidone | The risk or severity of adverse effects can be increased when Midazolam is combined with Etoperidone. | Approved |
| Etoposide | The serum concentration of Etoposide can be decreased when it is combined with Midazolam. | Approved |
| Etorphine | The risk or severity of adverse effects can be increased when Midazolam is combined with Etorphine. | Illicit, Vet Approved |
| Etravirine | The serum concentration of Midazolam can be decreased when it is combined with Etravirine. | Approved |
| Everolimus | The serum concentration of Everolimus can be increased when it is combined with Midazolam. | Approved |
| Ezetimibe | The serum concentration of Ezetimibe can be decreased when it is combined with Midazolam. | Approved |
| Ezogabine | The risk or severity of adverse effects can be increased when Midazolam is combined with Ezogabine. | Approved |
| Faldaprevir | The serum concentration of Midazolam can be increased when it is combined with Bi201335. | Investigational |
| Felbamate | The risk or severity of adverse effects can be increased when Midazolam is combined with Felbamate. | Approved |
| Felodipine | The serum concentration of Midazolam can be increased when it is combined with Felodipine. | Approved, Investigational |
| Fencamfamine | The risk or severity of adverse effects can be increased when Midazolam is combined with Fencamfamine. | Approved, Illicit, Withdrawn |
| Fentanyl | The serum concentration of Midazolam can be increased when it is combined with Fentanyl. | Approved, Illicit, Investigational, Vet Approved |
| Fesoterodine | The serum concentration of Fesoterodine can be decreased when it is combined with Midazolam. | Approved |
| Fexofenadine | The serum concentration of Fexofenadine can be decreased when it is combined with Midazolam. | Approved |
| Fidaxomicin | The serum concentration of Fidaxomicin can be decreased when it is combined with Midazolam. | Approved |
| Flibanserin | The risk or severity of adverse effects can be increased when Midazolam is combined with Flibanserin. | Approved |
| Fluconazole | The metabolism of Midazolam can be decreased when combined with Fluconazole. | Approved |
| Fludiazepam | The risk or severity of adverse effects can be increased when Midazolam is combined with Fludiazepam. | Approved, Illicit |
| Flunarizine | The risk or severity of adverse effects can be increased when Midazolam is combined with Flunarizine. | Approved |
| Flunitrazepam | The risk or severity of adverse effects can be increased when Midazolam is combined with Flunitrazepam. | Approved, Illicit |
| Fluoxetine | The serum concentration of Midazolam can be increased when it is combined with Fluoxetine. | Approved, Vet Approved |
| Flupentixol | The serum concentration of Midazolam can be increased when it is combined with Flupentixol. | Approved, Withdrawn |
| Fluphenazine | The serum concentration of Midazolam can be increased when it is combined with Fluphenazine. | Approved |
| Flurazepam | The serum concentration of Midazolam can be increased when it is combined with Flurazepam. | Approved, Illicit |
| Fluspirilene | The risk or severity of adverse effects can be increased when Midazolam is combined with Fluspirilene. | Approved |
| Fluticasone furoate | The serum concentration of Fluticasone furoate can be decreased when it is combined with Midazolam. | Approved |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Midazolam is combined with Fluticasone Propionate. | Approved |
| Fluvoxamine | The metabolism of Midazolam can be decreased when combined with Fluvoxamine. | Approved, Investigational |
| Fosamprenavir | The serum concentration of Midazolam can be increased when it is combined with Fosamprenavir. | Approved |
| Fosaprepitant | The serum concentration of Midazolam can be increased when it is combined with Fosaprepitant. | Approved |
| Fosinopril | The serum concentration of Midazolam can be increased when it is combined with Fosinopril. | Approved |
| Fosphenytoin | The serum concentration of Fosphenytoin can be increased when it is combined with Midazolam. | Approved |
| Fospropofol | The risk or severity of adverse effects can be increased when Midazolam is combined with Fospropofol. | Approved, Illicit |
| Fusidic Acid | The serum concentration of Midazolam can be increased when it is combined with Fusidic Acid. | Approved |
| Gabapentin | The risk or severity of adverse effects can be increased when Midazolam is combined with Gabapentin. | Approved, Investigational |
| Gabapentin Enacarbil | The risk or severity of adverse effects can be increased when Midazolam is combined with gabapentin enacarbil. | Approved |
| Gabexate | The serum concentration of Midazolam can be increased when it is combined with Gabexate. | Investigational |
| Gamma Hydroxybutyric Acid | The risk or severity of adverse effects can be increased when Midazolam is combined with Gamma Hydroxybutyric Acid. | Approved, Illicit |
| Gefitinib | The serum concentration of Gefitinib can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Geldanamycin | The serum concentration of Midazolam can be increased when it is combined with Geldanamycin. | Experimental |
| Gemcitabine | The serum concentration of Gemcitabine can be decreased when it is combined with Midazolam. | Approved |
| Genistein | The serum concentration of Midazolam can be increased when it is combined with Genistein. | Investigational |
| Gepirone | The risk or severity of adverse effects can be increased when Midazolam is combined with Gepirone. | Investigational |
| Ginkgo biloba | The serum concentration of Midazolam can be decreased when it is combined with Ginkgo biloba. | Approved, Nutraceutical |
| Glutethimide | The risk or severity of adverse effects can be increased when Midazolam is combined with Glutethimide. | Approved, Illicit |
| Glyburide | The serum concentration of Midazolam can be increased when it is combined with Glyburide. | Approved |
| GM6001 | The serum concentration of Midazolam can be increased when it is combined with GM6001. | Experimental |
| Gramicidin D | The serum concentration of Midazolam can be increased when it is combined with Gramicidin D. | Approved |
| Grazoprevir | The serum concentration of Grazoprevir can be decreased when it is combined with Midazolam. | Approved |
| Grepafloxacin | The serum concentration of Grepafloxacin can be decreased when it is combined with Midazolam. | Withdrawn |
| Guanfacine | The risk or severity of adverse effects can be increased when Midazolam is combined with Guanfacine. | Approved, Investigational |
| Halazepam | The risk or severity of adverse effects can be increased when Midazolam is combined with Halazepam. | Approved, Illicit, Withdrawn |
| Haloperidol | The serum concentration of Haloperidol can be decreased when it is combined with Midazolam. | Approved |
| Halothane | The risk or severity of adverse effects can be increased when Midazolam is combined with Halothane. | Approved, Vet Approved |
| Heroin | The risk or severity of adverse effects can be increased when Midazolam is combined with Heroin. | Approved, Illicit |
| Hexobarbital | The risk or severity of adverse effects can be increased when Midazolam is combined with Hexobarbital. | Approved |
| Hyaluronidase | The therapeutic efficacy of Midazolam can be decreased when used in combination with Hyaluronidase. | Approved, Investigational |
| Hydrocodone | Midazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. | Approved, Illicit |
| Hydrocortisone | The serum concentration of Hydrocortisone can be decreased when it is combined with Midazolam. | Approved, Vet Approved |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Midazolam. | Approved, Illicit |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Midazolam. | Approved |
| Ibuprofen | The serum concentration of Ibuprofen can be decreased when it is combined with Midazolam. | Approved |
| Idelalisib | The serum concentration of Midazolam can be increased when it is combined with Idelalisib. | Approved |
| Idraparinux | The serum concentration of Midazolam can be increased when it is combined with idraparinux. | Investigational |
| Iloperidone | The risk or severity of adverse effects can be increased when Midazolam is combined with Iloperidone. | Approved |
| Imatinib | The metabolism of Midazolam can be decreased when combined with Imatinib. | Approved |
| Imidapril | The serum concentration of Midazolam can be increased when it is combined with Imidapril. | Investigational |
| Imipramine | The serum concentration of Imipramine can be decreased when it is combined with Midazolam. | Approved |
| Indacaterol | The serum concentration of Indacaterol can be decreased when it is combined with Midazolam. | Approved |
| Indalpine | The risk or severity of adverse effects can be increased when Midazolam is combined with Indalpine. | Investigational, Withdrawn |
| Indinavir | The serum concentration of Midazolam can be increased when it is combined with Indinavir. | Approved |
| Indomethacin | The serum concentration of Indomethacin can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Irinotecan | The serum concentration of Irinotecan can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Isavuconazonium | The metabolism of Midazolam can be decreased when combined with Isavuconazonium. | Approved, Investigational |
| Isoflurane | The risk or severity of adverse effects can be increased when Midazolam is combined with Isoflurane. | Approved, Vet Approved |
| Isoflurophate | The serum concentration of Midazolam can be increased when it is combined with Isoflurophate. | Approved, Withdrawn |
| Isradipine | The metabolism of Midazolam can be decreased when combined with Isradipine. | Approved |
| Itraconazole | The serum concentration of Midazolam can be increased when it is combined with Itraconazole. | Approved, Investigational |
| Ivacaftor | The serum concentration of Midazolam can be increased when it is combined with Ivacaftor. | Approved |
| Ivermectin | The serum concentration of Ivermectin can be decreased when it is combined with Midazolam. | Approved, Vet Approved |
| Ixazomib | The serum concentration of Midazolam can be increased when it is combined with Ixazomib. | Approved |
| Josamycin | The serum concentration of Midazolam can be increased when it is combined with Josamycin. | Approved |
| Ketamine | The serum concentration of Midazolam can be increased when it is combined with Ketamine. | Approved, Vet Approved |
| Ketazolam | The serum concentration of Ketazolam can be decreased when it is combined with Midazolam. | Approved |
| Ketobemidone | The risk or severity of adverse effects can be increased when Midazolam is combined with Ketobemidone. | Approved |
| Ketoconazole | The serum concentration of Midazolam can be increased when it is combined with Ketoconazole. | Approved, Investigational |
| Ketoconazole | The metabolism of Midazolam can be decreased when combined with Ketoconazole. | Approved, Investigational |
| Kitasamycin | The serum concentration of Midazolam can be increased when it is combined with Kitasamycin. | Experimental |
| Lamivudine | The serum concentration of Lamivudine can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Lamotrigine | The serum concentration of Lamotrigine can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Lansoprazole | The serum concentration of Lansoprazole can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Lapatinib | The serum concentration of Midazolam can be increased when it is combined with Lapatinib. | Approved, Investigational |
| Ledipasvir | The serum concentration of Ledipasvir can be decreased when it is combined with Midazolam. | Approved |
| Lenalidomide | The serum concentration of Lenalidomide can be decreased when it is combined with Midazolam. | Approved |
| Lenvatinib | The serum concentration of Lenvatinib can be decreased when it is combined with Midazolam. | Approved |
| Lepirudin | The serum concentration of Midazolam can be increased when it is combined with Lepirudin. | Approved |
| Levetiracetam | The serum concentration of Levetiracetam can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Levobupivacaine | The risk or severity of adverse effects can be increased when Midazolam is combined with Levobupivacaine. | Approved |
| Levocabastine | The risk or severity of adverse effects can be increased when Midazolam is combined with Levocabastine. | Approved |
| Levocetirizine | The risk or severity of adverse effects can be increased when Midazolam is combined with Levocetirizine. | Approved |
| Levodopa | The risk or severity of adverse effects can be increased when Midazolam is combined with Levodopa. | Approved |
| Levofloxacin | The serum concentration of Levofloxacin can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Levomethadyl Acetate | The risk or severity of adverse effects can be increased when Midazolam is combined with Levomethadyl Acetate. | Approved |
| Levomilnacipran | The serum concentration of Levomilnacipran can be decreased when it is combined with Midazolam. | Approved |
| Levorphanol | The risk or severity of adverse effects can be increased when Midazolam is combined with Levorphanol. | Approved |
| Levothyroxine | The serum concentration of Midazolam can be decreased when it is combined with Levothyroxine. | Approved |
| Lidocaine | The serum concentration of Midazolam can be increased when it is combined with Lidocaine. | Approved, Vet Approved |
| Linagliptin | The serum concentration of Midazolam can be increased when it is combined with Linagliptin. | Approved |
| Liothyronine | The serum concentration of Midazolam can be decreased when it is combined with Liothyronine. | Approved, Vet Approved |
| Liotrix | The serum concentration of Midazolam can be decreased when it is combined with Liotrix. | Approved |
| Lisinopril | The serum concentration of Midazolam can be increased when it is combined with Lisinopril. | Approved, Investigational |
| Lithium | The risk or severity of adverse effects can be increased when Midazolam is combined with Lithium. | Approved |
| Lofentanil | The risk or severity of adverse effects can be increased when Midazolam is combined with Lofentanil. | Illicit |
| Lomitapide | The serum concentration of Midazolam can be increased when it is combined with Lomitapide. | Approved |
| Loperamide | The serum concentration of Loperamide can be decreased when it is combined with Midazolam. | Approved |
| Lopinavir | The serum concentration of Midazolam can be increased when it is combined with Lopinavir. | Approved |
| Loratadine | The serum concentration of Midazolam can be increased when it is combined with Loratadine. | Approved |
| Lorazepam | The risk or severity of adverse effects can be increased when Lorazepam is combined with Midazolam. | Approved |
| Losartan | The serum concentration of Losartan can be decreased when it is combined with Midazolam. | Approved |
| Lovastatin | The metabolism of Midazolam can be decreased when combined with Lovastatin. | Approved, Investigational |
| Loxapine | The risk or severity of adverse effects can be increased when Loxapine is combined with Midazolam. | Approved |
| Luliconazole | The serum concentration of Midazolam can be increased when it is combined with Luliconazole. | Approved |
| Lumacaftor | The serum concentration of Midazolam can be decreased when it is combined with Lumacaftor. | Approved |
| Lurasidone | The risk or severity of adverse effects can be increased when Midazolam is combined with Lurasidone. | Approved |
| Magnesium Sulfate | Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Midazolam. | Approved, Vet Approved |
| Mannitol | The serum concentration of Mannitol can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Maprotiline | The serum concentration of Midazolam can be increased when it is combined with Maprotiline. | Approved |
| Mebendazole | The serum concentration of Midazolam can be increased when it is combined with Mebendazole. | Approved, Vet Approved |
| Meclizine | The risk or severity of adverse effects can be increased when Midazolam is combined with Meclizine. | Approved |
| Medetomidine | The risk or severity of adverse effects can be increased when Midazolam is combined with Medetomidine. | Vet Approved |
| Mefloquine | The serum concentration of Midazolam can be increased when it is combined with Mefloquine. | Approved |
| Megestrol acetate | The serum concentration of Midazolam can be increased when it is combined with Megestrol acetate. | Approved, Vet Approved |
| Melatonin | The risk or severity of adverse effects can be increased when Midazolam is combined with Melatonin. | Approved, Nutraceutical, Vet Approved |
| Melperone | The risk or severity of adverse effects can be increased when Midazolam is combined with Melperone. | Approved |
| Mepivacaine | The risk or severity of adverse effects can be increased when Midazolam is combined with Mepivacaine. | Approved, Vet Approved |
| Meprobamate | The serum concentration of Midazolam can be increased when it is combined with Meprobamate. | Approved, Illicit |
| Mesoridazine | The risk or severity of adverse effects can be increased when Midazolam is combined with Mesoridazine. | Approved |
| Metaxalone | The risk or severity of adverse effects can be increased when Midazolam is combined with Metaxalone. | Approved |
| Methadone | Midazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone. | Approved |
| Methadyl Acetate | The risk or severity of adverse effects can be increased when Midazolam is combined with Methadyl Acetate. | Approved, Illicit |
| Methapyrilene | The risk or severity of adverse effects can be increased when Midazolam is combined with Methapyrilene. | Withdrawn |
| Methaqualone | The risk or severity of adverse effects can be increased when Midazolam is combined with Methaqualone. | Illicit, Withdrawn |
| Methocarbamol | The risk or severity of adverse effects can be increased when Midazolam is combined with Methocarbamol. | Approved, Vet Approved |
| Methohexital | The risk or severity of adverse effects can be increased when Methohexital is combined with Midazolam. | Approved |
| Methotrexate | The serum concentration of Methotrexate can be decreased when it is combined with Midazolam. | Approved |
| Methotrimeprazine | Midazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. | Approved |
| Methoxyflurane | The risk or severity of adverse effects can be increased when Midazolam is combined with Methoxyflurane. | Approved, Vet Approved |
| Methsuximide | The risk or severity of adverse effects can be increased when Midazolam is combined with Methsuximide. | Approved |
| Methylecgonine | The risk or severity of adverse effects can be increased when Midazolam is combined with ECGONINE METHYL ESTER. | Experimental |
| Methylphenobarbital | The risk or severity of adverse effects can be increased when Midazolam is combined with Methylphenobarbital. | Approved |
| Methylprednisolone | The serum concentration of Methylprednisolone can be decreased when it is combined with Midazolam. | Approved, Vet Approved |
| Metoprolol | The serum concentration of Metoprolol can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Metyrosine | Midazolam may increase the sedative activities of Metyrosine. | Approved |
| Mibefradil | The serum concentration of Midazolam can be increased when it is combined with Mibefradil. | Withdrawn |
| Miconazole | The serum concentration of Midazolam can be increased when it is combined with Miconazole. | Approved, Investigational, Vet Approved |
| Mifepristone | The serum concentration of Midazolam can be increased when it is combined with Mifepristone. | Approved, Investigational |
| Milnacipran | The risk or severity of adverse effects can be increased when Midazolam is combined with Milnacipran. | Approved |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Midazolam. | Approved, Investigational |
| Mirabegron | The serum concentration of Mirabegron can be decreased when it is combined with Midazolam. | Approved |
| Mirtazapine | Midazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. | Approved |
| Mitomycin | The serum concentration of Midazolam can be increased when it is combined with Mitomycin. | Approved |
| Mitotane | The serum concentration of Midazolam can be decreased when it is combined with Mitotane. | Approved |
| Mitoxantrone | The serum concentration of Mitoxantrone can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Modafinil | The serum concentration of Midazolam can be decreased when it is combined with Modafinil. | Approved, Investigational |
| Moexipril | The serum concentration of Midazolam can be increased when it is combined with Moexipril. | Approved |
| Molindone | The risk or severity of adverse effects can be increased when Midazolam is combined with Molindone. | Approved |
| Morphine | The serum concentration of Morphine can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Mycophenolate mofetil | The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Midazolam. | Approved, Investigational |
| N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline | The serum concentration of Midazolam can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline. | Experimental |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Midazolam. | Approved, Investigational |
| Nadolol | The serum concentration of Nadolol can be decreased when it is combined with Midazolam. | Approved |
| Nafamostat | The serum concentration of Midazolam can be increased when it is combined with Nafamostat. | Approved, Investigational |
| Nafcillin | The serum concentration of Midazolam can be decreased when it is combined with Nafcillin. | Approved |
| Nalbuphine | The risk or severity of adverse effects can be increased when Midazolam is combined with Nalbuphine. | Approved |
| Naloxegol | The serum concentration of Naloxegol can be increased when it is combined with Midazolam. | Approved |
| Naloxone | The serum concentration of Naloxone can be decreased when it is combined with Midazolam. | Approved, Vet Approved |
| Naltrexone | The serum concentration of Midazolam can be increased when it is combined with Naltrexone. | Approved, Investigational, Vet Approved |
| Naringenin | The serum concentration of Midazolam can be increased when it is combined with Naringenin. | Experimental |
| Nefazodone | The metabolism of Midazolam can be decreased when combined with Nefazodone. | Approved, Withdrawn |
| Nelfinavir | The serum concentration of Midazolam can be increased when it is combined with Nelfinavir. | Approved |
| Neostigmine | The serum concentration of Midazolam can be increased when it is combined with Neostigmine. | Approved, Vet Approved |
| Netupitant | The serum concentration of Midazolam can be increased when it is combined with Netupitant. | Approved |
| Nevirapine | The metabolism of Midazolam can be increased when combined with Nevirapine. | Approved |
| Nicardipine | The serum concentration of Nicardipine can be decreased when it is combined with Midazolam. | Approved |
| Nifedipine | The serum concentration of Midazolam can be decreased when it is combined with Nifedipine. | Approved |
| Nilotinib | The metabolism of Midazolam can be decreased when combined with Nilotinib. | Approved, Investigational |
| Nintedanib | The serum concentration of Nintedanib can be increased when it is combined with Midazolam. | Approved |
| Nisoldipine | The serum concentration of Midazolam can be increased when it is combined with Nisoldipine. | Approved |
| Nitrazepam | The serum concentration of Midazolam can be increased when it is combined with Nitrazepam. | Approved |
| Nitrendipine | The serum concentration of Midazolam can be increased when it is combined with Nitrendipine. | Approved |
| Nitroaspirin | The serum concentration of Midazolam can be increased when it is combined with Nitroaspirin. | Investigational |
| Nitrous oxide | The risk or severity of adverse effects can be increased when Midazolam is combined with Nitrous oxide. | Approved, Vet Approved |
| Nizatidine | The serum concentration of Nizatidine can be decreased when it is combined with Midazolam. | Approved |
| Norethisterone | The serum concentration of Midazolam can be decreased when it is combined with Norethisterone. | Approved |
| Norflurane | The risk or severity of adverse effects can be increased when Midazolam is combined with 1,1,1,2 Tetrafluoroethane. | Investigational |
| Normethadone | The risk or severity of adverse effects can be increased when Midazolam is combined with Normethadone. | Approved, Illicit |
| Nortriptyline | The risk or severity of adverse effects can be increased when Midazolam is combined with Nortriptyline. | Approved |
| Olanzapine | The risk or severity of adverse effects can be increased when Olanzapine is combined with Midazolam. | Approved, Investigational |
| Olaparib | The metabolism of Midazolam can be decreased when combined with Olaparib. | Approved |
| Oleandomycin | The serum concentration of Midazolam can be increased when it is combined with Oleandomycin. | Vet Approved |
| Olopatadine | The risk or severity of adverse effects can be increased when Midazolam is combined with Olopatadine. | Approved |
| Omapatrilat | The serum concentration of Midazolam can be increased when it is combined with Omapatrilat. | Investigational |
| Ombitasvir | The serum concentration of Ombitasvir can be decreased when it is combined with Midazolam. | Approved |
| Omeprazole | The serum concentration of Midazolam can be increased when it is combined with Omeprazole. | Approved, Investigational, Vet Approved |
| Ondansetron | The risk or severity of adverse effects can be increased when Midazolam is combined with Ondansetron. | Approved |
| Opium | The risk or severity of adverse effects can be increased when Midazolam is combined with Opium. | Approved, Illicit |
| Orphenadrine | Midazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. | Approved |
| Osanetant | The risk or severity of adverse effects can be increased when Midazolam is combined with Osanetant. | Investigational |
| Osimertinib | The serum concentration of Midazolam can be increased when it is combined with Osimertinib. | Approved |
| Otamixaban | The serum concentration of Midazolam can be increased when it is combined with Otamixaban. | Investigational |
| Oxazepam | The risk or severity of adverse effects can be increased when Midazolam is combined with Oxazepam. | Approved |
| Oxethazaine | The risk or severity of adverse effects can be increased when Midazolam is combined with Oxetacaine. | Investigational |
| Oxprenolol | The risk or severity of adverse effects can be increased when Midazolam is combined with Oxprenolol. | Approved |
| Oxybuprocaine | The risk or severity of adverse effects can be increased when Midazolam is combined with Oxybuprocaine. | Approved |
| Oxycodone | The risk or severity of adverse effects can be increased when Oxycodone is combined with Midazolam. | Approved, Illicit, Investigational |
| Oxymorphone | The risk or severity of adverse effects can be increased when Midazolam is combined with Oxymorphone. | Approved, Investigational, Vet Approved |
| P-Nitrophenol | The serum concentration of Midazolam can be increased when it is combined with P-Nitrophenol. | Experimental |
| Paclitaxel | The serum concentration of Paclitaxel can be decreased when it is combined with Midazolam. | Approved, Vet Approved |
| Palbociclib | The serum concentration of Midazolam can be increased when it is combined with Palbociclib. | Approved |
| Paliperidone | The risk or severity of adverse effects can be increased when Midazolam is combined with Paliperidone. | Approved |
| Palmitic Acid | The serum concentration of Midazolam can be increased when it is combined with Palmitic Acid. | Experimental |
| Panobinostat | The serum concentration of Panobinostat can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Pantoprazole | The serum concentration of Midazolam can be increased when it is combined with Pantoprazole. | Approved |
| Paraldehyde | Midazolam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. | Approved |
| Paroxetine | The serum concentration of Midazolam can be increased when it is combined with Paroxetine. | Approved, Investigational |
| Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Midazolam. | Approved |
| Pentazocine | The risk or severity of adverse effects can be increased when Pentazocine is combined with Midazolam. | Approved, Vet Approved |
| Pentobarbital | The metabolism of Midazolam can be increased when combined with Pentobarbital. | Approved, Vet Approved |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Midazolam. | Approved |
| Perazine | The risk or severity of adverse effects can be increased when Midazolam is combined with Perazine. | Investigational |
| Perindopril | The serum concentration of Midazolam can be increased when it is combined with Perindopril. | Approved |
| Perospirone | The risk or severity of adverse effects can be increased when Midazolam is combined with Perospirone. | Approved |
| Perphenazine | The risk or severity of adverse effects can be increased when Midazolam is combined with Perphenazine. | Approved |
| Pethidine | The risk or severity of adverse effects can be increased when Pethidine is combined with Midazolam. | Approved |
| Phenobarbital | The metabolism of Midazolam can be increased when combined with Phenobarbital. | Approved |
| Phenoxyethanol | The risk or severity of adverse effects can be increased when Midazolam is combined with Phenoxyethanol. | Approved |
| Phenytoin | The serum concentration of Phenytoin can be increased when it is combined with Midazolam. | Approved, Vet Approved |
| Phosphoramidon | The serum concentration of Midazolam can be increased when it is combined with Phosphoramidon. | Experimental |
| Pimozide | The serum concentration of Midazolam can be increased when it is combined with Pimozide. | Approved |
| Pipamperone | The risk or severity of adverse effects can be increased when Midazolam is combined with Pipamperone. | Approved |
| Pipotiazine | The risk or severity of adverse effects can be increased when Midazolam is combined with Pipotiazine. | Approved |
| Piritramide | The risk or severity of adverse effects can be increased when Midazolam is combined with Piritramide. | Investigational |
| Pitavastatin | The serum concentration of Pitavastatin can be decreased when it is combined with Midazolam. | Approved |
| Pizotifen | The risk or severity of adverse effects can be increased when Midazolam is combined with Pizotifen. | Approved |
| Platelet Activating Factor | The serum concentration of Midazolam can be decreased when it is combined with Platelet Activating Factor. | Experimental |
| Pomalidomide | The serum concentration of Pomalidomide can be decreased when it is combined with Midazolam. | Approved |
| Ponatinib | The serum concentration of Ponatinib can be decreased when it is combined with Midazolam. | Approved |
| Posaconazole | The metabolism of Midazolam can be decreased when combined with Posaconazole. | Approved, Investigational, Vet Approved |
| Pramipexole | Midazolam may increase the sedative activities of Pramipexole. | Approved, Investigational |
| Pramocaine | The risk or severity of adverse effects can be increased when Midazolam is combined with Pramocaine. | Approved |
| Pravastatin | The serum concentration of Pravastatin can be decreased when it is combined with Midazolam. | Approved |
| Prazepam | The risk or severity of adverse effects can be increased when Midazolam is combined with Prazepam. | Approved, Illicit |
| Prazosin | The serum concentration of Prazosin can be decreased when it is combined with Midazolam. | Approved |
| Prednisolone | The serum concentration of Prednisolone can be decreased when it is combined with Midazolam. | Approved, Vet Approved |
| Prednisone | The serum concentration of Prednisone can be decreased when it is combined with Midazolam. | Approved, Vet Approved |
| Pregabalin | The risk or severity of adverse effects can be increased when Pregabalin is combined with Midazolam. | Approved, Illicit, Investigational |
| Prilocaine | The risk or severity of adverse effects can be increased when Midazolam is combined with Prilocaine. | Approved |
| Primidone | The metabolism of Midazolam can be increased when combined with Primidone. | Approved, Vet Approved |
| Prinomastat | The serum concentration of Midazolam can be increased when it is combined with Prinomastat. | Investigational |
| Probenecid | The serum concentration of Midazolam can be increased when it is combined with Probenecid. | Approved |
| Procaine | The risk or severity of adverse effects can be increased when Midazolam is combined with Procaine. | Approved, Investigational, Vet Approved |
| Prochlorperazine | The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Midazolam. | Approved, Vet Approved |
| Progesterone | The serum concentration of Midazolam can be decreased when it is combined with Progesterone. | Approved, Vet Approved |
| Promazine | The risk or severity of adverse effects can be increased when Promazine is combined with Midazolam. | Approved, Vet Approved |
| Promethazine | The serum concentration of Midazolam can be increased when it is combined with Promethazine. | Approved |
| Propafenone | The serum concentration of Midazolam can be increased when it is combined with Propafenone. | Approved |
| Proparacaine | The risk or severity of adverse effects can be increased when Midazolam is combined with Proparacaine. | Approved, Vet Approved |
| Propofol | The serum concentration of Propofol can be increased when it is combined with Midazolam. | Approved, Investigational, Vet Approved |
| Propoxycaine | The risk or severity of adverse effects can be increased when Midazolam is combined with Propoxycaine. | Approved |
| Propranolol | The serum concentration of Propranolol can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Protriptyline | The serum concentration of Midazolam can be increased when it is combined with Protriptyline. | Approved |
| Prucalopride | The serum concentration of Prucalopride can be increased when it is combined with Midazolam. | Approved |
| PSD502 | The risk or severity of adverse effects can be increased when Midazolam is combined with PSD502. | Investigational |
| Quazepam | The serum concentration of Midazolam can be increased when it is combined with Quazepam. | Approved, Illicit |
| Quercetin | The serum concentration of Midazolam can be increased when it is combined with Quercetin. | Experimental |
| Quetiapine | The serum concentration of Quetiapine can be decreased when it is combined with Midazolam. | Approved |
| Quinacrine | The serum concentration of Midazolam can be increased when it is combined with Quinacrine. | Approved |
| Quinapril | The serum concentration of Midazolam can be increased when it is combined with Quinapril. | Approved, Investigational |
| Quinidine | The serum concentration of Quinidine can be decreased when it is combined with Midazolam. | Approved |
| Quinine | The serum concentration of Quinine can be decreased when it is combined with Midazolam. | Approved |
| Racecadotril | The serum concentration of Midazolam can be increased when it is combined with Racecadotril. | Investigational |
| Raclopride | The risk or severity of adverse effects can be increased when Midazolam is combined with Raclopride. | Investigational |
| Ramelteon | The risk or severity of adverse effects can be increased when Midazolam is combined with Ramelteon. | Approved, Investigational |
| Ramipril | The serum concentration of Midazolam can be increased when it is combined with Ramipril. | Approved |
| Ranitidine | The serum concentration of Ranitidine can be decreased when it is combined with Midazolam. | Approved |
| Ranolazine | The serum concentration of Ranolazine can be increased when it is combined with Midazolam. | Approved, Investigational |
| Reboxetine | The serum concentration of Midazolam can be increased when it is combined with Reboxetine. | Approved, Investigational |
| Regorafenib | The serum concentration of Midazolam can be increased when it is combined with Regorafenib. | Approved |
| Remifentanil | The risk or severity of adverse effects can be increased when Midazolam is combined with Remifentanil. | Approved |
| Remikiren | The serum concentration of Midazolam can be increased when it is combined with Remikiren. | Approved |
| Remoxipride | The risk or severity of adverse effects can be increased when Remoxipride is combined with Midazolam. | Approved, Withdrawn |
| Reserpine | The serum concentration of Midazolam can be decreased when it is combined with Reserpine. | Approved |
| Rifabutin | The metabolism of Midazolam can be increased when combined with Rifabutin. | Approved |
| Rifampicin | The metabolism of Midazolam can be increased when combined with Rifampicin. | Approved |
| Rifapentine | The metabolism of Midazolam can be increased when combined with Rifapentine. | Approved |
| Rifaximin | The serum concentration of Rifaximin can be increased when it is combined with Midazolam. | Approved, Investigational |
| Rilpivirine | The serum concentration of Midazolam can be increased when it is combined with Rilpivirine. | Approved |
| Risperidone | The serum concentration of Risperidone can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Ritanserin | The risk or severity of adverse effects can be increased when Midazolam is combined with Ritanserin. | Investigational |
| Ritonavir | The serum concentration of Midazolam can be increased when it is combined with Ritonavir. | Approved, Investigational |
| Rivaroxaban | The serum concentration of Midazolam can be increased when it is combined with Rivaroxaban. | Approved |
| Rolapitant | The serum concentration of Midazolam can be increased when it is combined with Rolapitant. | Approved |
| Romidepsin | The serum concentration of Romidepsin can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Romifidine | The risk or severity of adverse effects can be increased when Midazolam is combined with Romifidine. | Vet Approved |
| Ropinirole | Midazolam may increase the sedative activities of Ropinirole. | Approved, Investigational |
| Ropivacaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Midazolam. | Approved |
| Rotigotine | Midazolam may increase the sedative activities of Rotigotine. | Approved |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Midazolam. | Approved |
| Salicylic acid | The serum concentration of Salicylic acid can be decreased when it is combined with Midazolam. | Approved, Vet Approved |
| Saquinavir | The serum concentration of Midazolam can be increased when it is combined with Saquinavir. | Approved, Investigational |
| Saxagliptin | The serum concentration of Midazolam can be increased when it is combined with Saxagliptin. | Approved |
| Scopolamine | The serum concentration of Midazolam can be increased when it is combined with Scopolamine. | Approved |
| Secobarbital | The risk or severity of adverse effects can be increased when Secobarbital is combined with Midazolam. | Approved, Vet Approved |
| Selegiline | The serum concentration of Midazolam can be increased when it is combined with Selegiline. | Approved, Investigational, Vet Approved |
| Selexipag | The serum concentration of Selexipag can be decreased when it is combined with Midazolam. | Approved |
| Sepranolone | The risk or severity of adverse effects can be increased when Midazolam is combined with Uc1010. | Investigational |
| Sertindole | The risk or severity of adverse effects can be increased when Midazolam is combined with Sertindole. | Approved, Withdrawn |
| Sertraline | The serum concentration of Midazolam can be increased when it is combined with Sertraline. | Approved |
| Sevoflurane | The risk or severity of adverse effects can be increased when Midazolam is combined with Sevoflurane. | Approved, Vet Approved |
| Sildenafil | The metabolism of Midazolam can be decreased when combined with Sildenafil. | Approved, Investigational |
| Silodosin | The serum concentration of Silodosin can be increased when it is combined with Midazolam. | Approved |
| Siltuximab | The serum concentration of Midazolam can be decreased when it is combined with Siltuximab. | Approved |
| Simeprevir | The serum concentration of Midazolam can be increased when it is combined with Simeprevir. | Approved |
| Simvastatin | The serum concentration of Midazolam can be increased when it is combined with Simvastatin. | Approved |
| Sirolimus | The serum concentration of Midazolam can be decreased when it is combined with Sirolimus. | Approved, Investigational |
| Sitagliptin | The serum concentration of Midazolam can be increased when it is combined with Sitagliptin. | Approved, Investigational |
| Sodium oxybate | Midazolam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. | Approved |
| Sofosbuvir | The serum concentration of Sofosbuvir can be decreased when it is combined with Midazolam. | Approved |
| Solithromycin | The serum concentration of Midazolam can be increased when it is combined with Solithromycin. | Investigational |
| Sorafenib | The serum concentration of Sorafenib can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Sparfloxacin | The serum concentration of Sparfloxacin can be decreased when it is combined with Midazolam. | Approved |
| Sphingosine | The serum concentration of Sphingosine can be decreased when it is combined with Midazolam. | Experimental |
| Spirapril | The serum concentration of Midazolam can be increased when it is combined with Spirapril. | Approved |
| Spironolactone | The serum concentration of Midazolam can be increased when it is combined with Spironolactone. | Approved |
| St. John's Wort | The serum concentration of Midazolam can be decreased when it is combined with St. John's Wort. | Nutraceutical |
| Staurosporine | The serum concentration of Midazolam can be increased when it is combined with Staurosporine. | Experimental |
| Stiripentol | The serum concentration of Midazolam can be increased when it is combined with Stiripentol. | Approved |
| Streptozocin | The serum concentration of Midazolam can be decreased when it is combined with Streptozocin. | Approved |
| Sufentanil | The risk or severity of adverse effects can be increased when Midazolam is combined with Sufentanil. | Approved, Investigational |
| Sulfinpyrazone | The serum concentration of Midazolam can be increased when it is combined with Sulfinpyrazone. | Approved |
| Sulfisoxazole | The metabolism of Midazolam can be decreased when combined with Sulfisoxazole. | Approved, Vet Approved |
| Sulpiride | The risk or severity of adverse effects can be increased when Sulpiride is combined with Midazolam. | Approved |
| Sumatriptan | The serum concentration of Midazolam can be increased when it is combined with Sumatriptan. | Approved, Investigational |
| Sunitinib | The serum concentration of Midazolam can be increased when it is combined with Sunitinib. | Approved, Investigational |
| Suvorexant | Midazolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. | Approved |
| Tacrine | The serum concentration of Midazolam can be increased when it is combined with Tacrine. | Withdrawn |
| Tacrolimus | The serum concentration of Midazolam can be decreased when it is combined with Tacrolimus. | Approved, Investigational |
| Tamoxifen | The serum concentration of Tamoxifen can be decreased when it is combined with Midazolam. | Approved |
| Tandospirone | The risk or severity of adverse effects can be increased when Midazolam is combined with Tandospirone. | Investigational |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Midazolam. | Approved |
| Tasimelteon | The risk or severity of adverse effects can be increased when Midazolam is combined with Tasimelteon. | Approved |
| Taurocholic Acid | The serum concentration of Taurocholic Acid can be decreased when it is combined with Midazolam. | Experimental |
| Technetium Tc-99m sestamibi | The serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Midazolam. | Approved |
| Teduglutide | The serum concentration of Midazolam can be increased when it is combined with Teduglutide. | Approved |
| Telaprevir | The serum concentration of Midazolam can be increased when it is combined with Telaprevir. | Withdrawn |
| Telithromycin | The serum concentration of Midazolam can be increased when it is combined with Telithromycin. | Approved |
| Telmisartan | The serum concentration of Midazolam can be increased when it is combined with Telmisartan. | Approved, Investigational |
| Temazepam | The risk or severity of adverse effects can be increased when Temazepam is combined with Midazolam. | Approved |
| Temocapril | The serum concentration of Midazolam can be increased when it is combined with Temocapril. | Experimental, Investigational |
| Temsirolimus | The serum concentration of Temsirolimus can be decreased when it is combined with Midazolam. | Approved |
| Terazosin | The serum concentration of Midazolam can be increased when it is combined with Terazosin. | Approved |
| Terfenadine | The serum concentration of Midazolam can be increased when it is combined with Terfenadine. | Withdrawn |
| Tesmilifene | The serum concentration of Midazolam can be decreased when it is combined with Tesmilifene. | Investigational |
| Testosterone | The serum concentration of Midazolam can be increased when it is combined with Testosterone. | Approved, Investigational |
| Tetrabenazine | The risk or severity of adverse effects can be increased when Midazolam is combined with Tetrabenazine. | Approved |
| Tetracaine | The risk or severity of adverse effects can be increased when Midazolam is combined with Tetracaine. | Approved, Vet Approved |
| Tetrodotoxin | The risk or severity of adverse effects can be increased when Midazolam is combined with Tetrodotoxin. | Investigational |
| Thalidomide | Midazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. | Approved, Investigational, Withdrawn |
| Theophylline | The therapeutic efficacy of Midazolam can be decreased when used in combination with Theophylline. | Approved |
| Thiamylal | The risk or severity of adverse effects can be increased when Midazolam is combined with Thiamylal. | Approved, Vet Approved |
| Thiopental | The risk or severity of adverse effects can be increased when Thiopental is combined with Midazolam. | Approved, Vet Approved |
| Thioridazine | The risk or severity of adverse effects can be increased when Thioridazine is combined with Midazolam. | Withdrawn |
| Thiorphan | The serum concentration of Midazolam can be increased when it is combined with Thiorphan. | Experimental |
| Thiotepa | The metabolism of Midazolam can be decreased when combined with Thiotepa. | Approved |
| Thiothixene | The risk or severity of adverse effects can be increased when Midazolam is combined with Thiothixene. | Approved |
| Tiagabine | The risk or severity of adverse effects can be increased when Midazolam is combined with Tiagabine. | Approved |
| Tiapride | The risk or severity of adverse effects can be increased when Midazolam is combined with Tiapride. | Approved, Investigational |
| Ticagrelor | The serum concentration of Ticagrelor can be decreased when it is combined with Midazolam. | Approved |
| Ticlopidine | The metabolism of Midazolam can be decreased when combined with Ticlopidine. | Approved |
| Tiletamine | The risk or severity of adverse effects can be increased when Midazolam is combined with Tiletamine. | Vet Approved |
| Timolol | The serum concentration of Timolol can be decreased when it is combined with Midazolam. | Approved |
| Tipranavir | The serum concentration of Midazolam can be increased when it is combined with Tipranavir. | Approved, Investigational |
| Tizanidine | The risk or severity of adverse effects can be increased when Midazolam is combined with Tizanidine. | Approved |
| Tocilizumab | The serum concentration of Midazolam can be decreased when it is combined with Tocilizumab. | Approved |
| Tolcapone | The risk or severity of adverse effects can be increased when Midazolam is combined with Tolcapone. | Approved, Withdrawn |
| Tolvaptan | The serum concentration of Tolvaptan can be decreased when it is combined with Midazolam. | Approved |
| Topiramate | The risk or severity of adverse effects can be increased when Midazolam is combined with Topiramate. | Approved |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Midazolam. | Approved, Investigational |
| Toremifene | The serum concentration of Toremifene can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Tramadol | The risk or severity of adverse effects can be increased when Tramadol is combined with Midazolam. | Approved, Investigational |
| Trandolapril | The serum concentration of Midazolam can be increased when it is combined with Trandolapril. | Approved |
| Trans-2-Phenylcyclopropylamine | The risk or severity of adverse effects can be increased when Midazolam is combined with Trans-2-Phenylcyclopropylamine. | Experimental |
| Tranylcypromine | The risk or severity of adverse effects can be increased when Midazolam is combined with Tranylcypromine. | Approved |
| Trastuzumab emtansine | The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Midazolam. | Approved |
| Trazodone | The serum concentration of Midazolam can be decreased when it is combined with Trazodone. | Approved, Investigational |
| Triazolam | The risk or severity of adverse effects can be increased when Midazolam is combined with Triazolam. | Approved |
| Trifluoperazine | The serum concentration of Midazolam can be increased when it is combined with Trifluoperazine. | Approved |
| Triflupromazine | The serum concentration of Midazolam can be increased when it is combined with Triflupromazine. | Approved, Vet Approved |
| Trimethoprim | The serum concentration of Midazolam can be decreased when it is combined with Trimethoprim. | Approved, Vet Approved |
| Trimipramine | The serum concentration of Midazolam can be increased when it is combined with Trimipramine. | Approved |
| Triprolidine | The risk or severity of adverse effects can be increased when Midazolam is combined with Triprolidine. | Approved |
| Tylosin | The serum concentration of Midazolam can be increased when it is combined with Tylosin. | Vet Approved |
| Ubenimex | The serum concentration of Midazolam can be increased when it is combined with Ubenimex. | Experimental |
| Ulinastatin | The serum concentration of Midazolam can be increased when it is combined with Ulinastatin. | Investigational |
| Ulipristal | The serum concentration of Ulipristal can be decreased when it is combined with Midazolam. | Approved |
| Umeclidinium | The serum concentration of Umeclidinium can be decreased when it is combined with Midazolam. | Approved |
| Valproic Acid | The risk or severity of adverse effects can be increased when Valproic Acid is combined with Midazolam. | Approved, Investigational |
| Vecuronium | The serum concentration of Vecuronium can be decreased when it is combined with Midazolam. | Approved |
| Venetoclax | The serum concentration of Venetoclax can be decreased when it is combined with Midazolam. | Approved |
| Venlafaxine | The metabolism of Midazolam can be decreased when combined with Venlafaxine. | Approved |
| Verapamil | The metabolism of Midazolam can be decreased when combined with Verapamil. | Approved |
| Vigabatrin | The risk or severity of adverse effects can be increased when Midazolam is combined with Vigabatrin. | Approved |
| Vildagliptin | The serum concentration of Midazolam can be increased when it is combined with Vildagliptin. | Approved, Investigational |
| Vinblastine | The serum concentration of Vinblastine can be decreased when it is combined with Midazolam. | Approved |
| Vincristine | The serum concentration of Vincristine can be decreased when it is combined with Midazolam. | Approved, Investigational |
| Vinorelbine | The serum concentration of Midazolam can be increased when it is combined with Vinorelbine. | Approved, Investigational |
| Vismodegib | The serum concentration of Vismodegib can be decreased when it is combined with Midazolam. | Approved |
| Voriconazole | The metabolism of Midazolam can be decreased when combined with Voriconazole. | Approved, Investigational |
| Vortioxetine | The risk or severity of adverse effects can be increased when Midazolam is combined with Vortioxetine. | Approved |
| Ximelagatran | The serum concentration of Midazolam can be increased when it is combined with Ximelagatran. | Approved, Investigational, Withdrawn |
| Xylazine | The risk or severity of adverse effects can be increased when Midazolam is combined with Xylazine. | Vet Approved |
| Yohimbine | The therapeutic efficacy of Midazolam can be decreased when used in combination with Yohimbine. | Approved, Vet Approved |
| Zaleplon | The risk or severity of adverse effects can be increased when Midazolam is combined with Zaleplon. | Approved, Illicit, Investigational |
| Ziconotide | The risk or severity of adverse effects can be increased when Midazolam is combined with Ziconotide. | Approved |
| Zidovudine | The serum concentration of Zidovudine can be decreased when it is combined with Midazolam. | Approved |
| Zimelidine | The serum concentration of Midazolam can be increased when it is combined with Zimelidine. | Withdrawn |
| Ziprasidone | The metabolism of Midazolam can be decreased when combined with Ziprasidone. | Approved |
| Zolazepam | The risk or severity of adverse effects can be increased when Midazolam is combined with Zolazepam. | Vet Approved |
| Zolpidem | Midazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. | Approved |
| Zonisamide | The risk or severity of adverse effects can be increased when Midazolam is combined with Zonisamide. | Approved, Investigational |
| Zopiclone | The risk or severity of adverse effects can be increased when Midazolam is combined with Zopiclone. | Approved |
| Zotepine | The risk or severity of adverse effects can be increased when Midazolam is combined with Zotepine. | Approved |
| Zuclopenthixol | The risk or severity of adverse effects can be increased when Midazolam is combined with Zuclopenthixol. | Approved, Investigational |
